Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT05691257

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05691257
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05691257. Non-randomized; no masking; primary purpose treatment. Start 2023-02-01 (anticipated); primary completion 2023-08-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
Condition
Heart Failure
Condition
Chronic Kidney Diseases
Condition
Anemia
Intervention (Drug)
Roxadustat
Intervention (Drug)
Recombinant human eythropoietin and/or Iron agents
Lead sponsor
China-Japan Friendship Hospital (class: other)

Record details

Record id
cardio:ct-nct05691257
Content hash
ee1923b3d341824af7b101f9e4e6c4f3d955f83526877258328e2e4d1cd0f4ab